- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04083079
Cost-Effectiveness Study of PEG-rhG-CSF in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma
Cost-Effectiveness Study of Pegylated Recombinant Human Granulocyte Colony-stimulating Factor(PEG-rhG-CSF) in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Weili Zhao, PhD
- Phone Number: 610707 +86 021 6437045
- Email: zhao.weili@yahoo.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200025
- Recruiting
- Ruijin Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18-65 years
- histologically confirmed de novo Non Hodgkin's lymphoma (except highly aggressive lymphoma such as lymphoblastic lymphoma and Burkitt lymphoma)
- plan to be given 6-8 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) ± Rituximab (R)
- KPS ≥70
- plan continuous PEG-rhG-CSF or rhG-CSF adiministration after at least 3 cycles of treatment for neutropenia prophylactic treatment
- absolute neutrophil count≥1.5×109/L,platelet count ≥100× 109/L,hemoglobin≥90g/L,while blood cell count≥3.0×109/L,without bleeding signs
- adquate liver and renal function as protocol discribed
- no serious cardiovascular disease as protocol discribed
- under good mental conditions and informed consented
- potential benefit for subjects based on investigators' decision
Exclusion Criteria:
- history of hematopoetic stem cell transplantationor organ transplantation
- uncontrollable infection
- allergic to study drugs or ingredients
- accepted any other investigational drug or participated another interventional study within 30 days during screening period
- other uncontrollable conditions judged by the investigator
- breast-feeding , pregnant or plan to be pregnant during study observation period
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PEG-rhG-CSF cohort
PEG-rhG-CSF primary/secondary prevention will be given 24-72 hours after each cycle for only once. Dosage: 6mg for weight ≥45kg,3mg for weight <45kg, subcutaneous injection |
Patients will be given PEG-rhG-CSF for primary/secondary prevention each cycle.
|
Experimental: rhG-CSF cohort
rhG-CSF primary/secondary prevention will be given 24-72 hours after each cycle until absolute neutrophil count ≥2×10^9/L. rhG-CSF treatment will be given when there is neutropenia until absolute neutrophil count ≥2×10^9/L. Dosage: 5μg/kg/d, subcutaneous injection |
Patients will be given rhG-CSF for either primary/secondary prevention or treatment once any neutropenia each cycle.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incremental Cost-Effectiveness ratio
Time Frame: 1 year
|
A comparison of the different strategies based on the incremental cost-effectiveness ratio (ICER), which is defined by the difference in costs between interventions, divided by the difference in their measured impact
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cost-Effectiveness ratio
Time Frame: 1 year
|
A comparison of the different strategies based on the cost-effectiveness ratio (ICER), which is defined by the difference in costs between interventions, divided by the difference in their measured impact
|
1 year
|
Sensitivity analysis
Time Frame: 1 year
|
A sensitivity analysis is a way of examining Sensitivity to Change in results due to changes in the parameter values applied within a certain scope.
|
1 year
|
Incidence of febrile neutropenia
Time Frame: 1 year
|
Incidence of febrile neutropenia (i.e.
absolute neutrophil count<0.5×10^9/L
and temperature ≥38℃)in each cycle
|
1 year
|
Duration time of febrile neutropenia
Time Frame: 1 year
|
Duration time of febrile neutropenia (i.e.
absolute neutrophil count<0.5×10^9/L
and temperature ≥38℃)in each cycle
|
1 year
|
Incidence of grade 3-4 neutropenia
Time Frame: 1 year
|
Incidence of grade 3-4 neutropenia(i.e.
absolute neutrophil count<1×10^9/L)in each cycle
|
1 year
|
Duration time of grade 3-4 neutropenia
Time Frame: 1 year
|
Duration time of grade 3-4 neutropenia(i.e.
absolute neutrophil count<1×10^9/L)in each cycle
|
1 year
|
Relative dosage intensity
Time Frame: 1 year
|
comparison between planned and actual chemotherapy dosage in each cycle
|
1 year
|
Usage rate of antibiotics
Time Frame: 1 year
|
Usage rate of antibiotics during study period
|
1 year
|
Adverse events
Time Frame: 1 year
|
incidence and severity of adverse events during study period
|
1 year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PEG-rhG-CSF-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma, Non-Hodgkin
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin LymphomaUnited States
-
Marker Therapeutics, Inc.RecruitingNon Hodgkin Lymphoma | Non-Hodgkin Lymphoma, Adult | Non-Hodgkin Lymphoma, Refractory | Non-Hodgkin Lymphoma, RelapsedUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
National Cancer Institute (NCI)RecruitingRefractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Primary Cutaneous... and other conditionsUnited States
-
Caribou Biosciences, Inc.RecruitingLymphoma | Lymphoma, Non-Hodgkin | B Cell Lymphoma | Non Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | B Cell Non-Hodgkin's LymphomaUnited States, Australia, Israel
-
Mayo ClinicNot yet recruitingIndolent B-Cell Non-Hodgkin Lymphoma | Recurrent Indolent Non-Hodgkin Lymphoma | Refractory Indolent Non-Hodgkin Lymphoma | Recurrent Indolent B-Cell Non-Hodgkin Lymphoma | Refractory Indolent B-Cell Non-Hodgkin LymphomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRefractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Hematopoietic Cell Transplantation RecipientUnited States
-
Chongqing Precision Biotech Co., LtdRecruitingNon Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Relapsed Non-Hodgkin LymphomaChina
-
University of WashingtonRecruitingRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin LymphomaUnited States
-
Estrella Biopharma, Inc.Eureka Therapeutics Inc.Not yet recruitingLymphoma | Lymphoma, Non-Hodgkin | Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | CNS Lymphoma | Lymphomas Non-Hodgkin's B-Cell | Relapsed Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkins | Large B-Cell Lymphoma and other conditions
Clinical Trials on PEG-rhG-CSF
-
Peking UniversityUnknown
-
Chongqing University Cancer HospitalCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.Recruiting
-
Air Force Military Medical University, ChinaUnknown
-
Sun Yat-sen UniversityJiangsu HengRui Medicine Co., Ltd.Not yet recruiting
-
Xiamen Amoytop Biotech Co., Ltd.Cancer Institute and Hospital, Chinese Academy of Medical SciencesCompletedNon-Myeloid MalignancyChina
-
Adello Biologics, LLCinVentiv Health ClinicalCompletedHealthy VolunteersUnited States
-
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.Hebei Medical University Fourth HospitalUnknown
-
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.Peking University Cancer Hospital & InstituteUnknownSmall Cell Lung Cancer | PEG-rhG-CSFChina
-
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.Beijing Friendship HospitalUnknownHemophagocytic SyndromeChina
-
Mabwell (Shanghai) Bioscience Co., Ltd.Completed